Mucopolysaccharidosis Type IIIA (MPS III), or Sanfilippo syndrome, is a rare, multisystem lysosomal storage disorder (LSD) that causes severe intellectual disability, developmental regression, and various neurological symptoms. Despite FDA approval of new therapies, payer restrictions, and complex reimbursement processes often limit access to these treatments.
This white paper explores the current climate in LSDs and provides strategies to enhance payer formulary placement and reimbursement, ultimately improving patient access.
Read the full white paper to learn more.
